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Abstract
Background: For elderly or medically unfit patients with muscle-invasive bladder cancer, cystectomy or
chemotherapy are contraindicated. This leaves radical radiotherapy as the only treatment option. It was the aim of
this study to retrospectively analyze the treatment outcome and associated toxicity of conformal versus intensity-
modulated radiotherapy (IMRT) using a focal simultaneous tumor boost for muscle-invasive bladder cancer in
patients not suitable for cystectomy.
Methods: One hundred eighteen patients with T2-4 N0-1 M0 bladder cancer were analyzed retrospectively. Median
age was 80 years. Treatment consisted of either a conformal box technique or IMRT and included a simultaneous
boost to the tumor. To enable an accurate boost delivery, fiducial markers were placed around the tumor. Patients
were treated with 40 Gy in 20 fractions to the elective treatment volumes, and a daily tumor boost up to 55–60 Gy.
Results: Clinical complete response was seen in 87 % of patients. Three-year overall survival was 44 %, with a
locoregional control rate of 73 % at 3 years. Toxicity was low, with late urinary and intestinal toxicity rates grade≥ 2
of 14 and 5 %, respectively. The use of IMRT reduced late intestinal toxicity, whereas fiducial markers reduced acute
urinary toxicity.
Conclusions: Radical radiotherapy using a focal boost is feasible and effective for elderly or unfit patients, with a
3-year locoregional control of 73 %. Toxicity rates were low, and were reduced by the use of IMRT and fiducial
markers.
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Background
Standard therapy for muscle-invasive bladder cancer is
radical cystectomy with bilateral lymph node dissection
[1], providing 3-year recurrence-free survival rates of
60–68 % [2–5]. Bladder-preserving strategies, such as
trimodality treatments combining radiochemotherapy
with a transurethral resection of the bladder tumor
(TUR-B) are usually only offered to patients who refuse
cystectomy or who are considered inoperable [6–8]. The
superiority of surgery over a bladder-preserving strategy
has not been proven in a randomized trial, although
long-term data shows that overall survival for both strat-
egies is comparable [1, 9–11]. It has been shown that a
combination of radiotherapy and chemotherapy results
in a higher locoregional control and overall survival
compared to radiotherapy alone [6, 12, 13], resulting in
radiochemotherapy being the preferred bladder-sparing
treatment option. However, patients who are referred for
bladder-sparing approaches are mostly elderly or unfit,
which regularly also contraindicates chemotherapy [14].* Correspondence: l.j.lutkenhaus@amc.uva.nl
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This leaves the combination of TUR-B and radical radio-
therapy as the only treatment option.
Radiotherapy techniques have improved over the past
years, from box techniques incorporating the entire pelvis,
to adaptive strategies combined with rotational delivery re-
ducing normal tissue doses [15–21]. For radical radiother-
apy delivered with large, non-modulated treatment fields
for both the bladder and the tumor boost area, without
using daily image-guidance, relatively low three-year local
control rates of 53–56 % have been reported [22–24]. For
these radiotherapy treatments, with tumor doses between
55 and 70 Gy, acute and late toxicity rates grade ≥ 2 ranged
between 20–67 %, and 7–17 %, respectively [22, 25–29].
More conformal treatment plans have shown to result in
reduced toxicity [26], and seem promising in terms of local
control when combined with daily image-guidance [30–32].
However, these studies consist of small patient numbers,
and frequently have a short follow-up.
The aim of the present retrospective study was to
analyze the treatment outcome and associated toxicity
of conformal versus intensity-modulated radiotherapy,
without concurrent chemotherapy, using a focal simultan-
eous boost for muscle-invasive bladder cancer in patients
considered medically or technically inoperable.
Methods
From 2003 to 2013, 132 patients with a muscle-invasive
urothelial cell carcinoma of the bladder were treated
with radical radiotherapy at the Academic Medical Center,
The Netherlands. Of these, 8 patients were also included
in a previous analysis [23]. Inclusion of patients was
started upon implementation of an adaptive strategy [17],
which yielded the range of used treatment techniques as
homogeneous as we could achieve. Patients with multiple
tumors were excluded, resulting in 118 patients available
for analysis. The results were evaluated retrospectively.
Patient and treatment characteristics are shown in Table 1.
Median age at start of radiotherapy was 80 years (range:
41–95 years). All patients had a histologically diagnosed
solitary T2-4 N0-1 M0 bladder tumor, and were inoper-
able, refused surgery or were medically unfit for radical
surgery due to age or comorbidities. Staging procedures
included clinical and digital rectal examination, chest X-
ray, a pelvic and abdominal CT scan and cystoscopy. All
patients underwent TUR-B prior to radiotherapy. Tumors
were scored as T3 when a mass was palpated after the
TUR-B, or when the CT scan revealed tumor extension in
the perivesical fatty tissue. When muscle infiltration depth
was unknown, the tumor was scored as T2.
Radiotherapy
Patients were treated in 20 daily fractions, over a period
of 4 weeks. The prescription dose to the elective area,
i.e. bladder, prostate and pelvic lymph nodes, was 40 Gy.

























2–4 cm 37 (31)
4–6 cm 58 (49)
≥6 cm 22 (19)
Unknown 1 (1)
Tumor resection status
Not resected 2 (2)
Complete resection 13 (11)
Incomplete resection 49 (41)
Unknown 54 (46)
Planned radiotherapy dose
55 Gy 61 (52)







Simultaneously integrated 17 (14)
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Lymph nodes were excluded from the elective field in
case of comorbidities that required a target volume re-
duction. The tumor received a simultaneous boost of
0.75 Gy, delivered either concomitantly or simultan-
eously integrated with the elective dose. Before 2006, a
total prescription dose of 55 Gy to the tumor was used.
After 2006, a dose of 60 Gy was chosen, unless this
would result in a too high small bowel dose (bowel vol-
ume receiving 60 Gy > 3 cm3). It was chosen to increase
the tumor dose, since a previously conducted study at
our institute showed a low toxicity profile for the 55 Gy
schedule [23], leaving room for dose escalation and tak-
ing into account that no concurrent chemotherapy was
administered. The additional 5 Gy dose was delivered in
two fractions of 2.5 Gy at the end of treatment.
A CT scan with contrast filling for the bowel was ac-
quired prior to treatment and used for planning pur-
poses. Patients were instructed to have a full bladder
during CT scanning and during treatment, by drinking
250 ml of fluid 1.5 h prior to treatment, and refrain from
voiding in order to minimize the volume of non-
involved bladder tissue receiving the boost dose. The
bladder and gross tumor volume (GTV) were delineated
on the planning CT scan. From 2004 onwards, GTV delin-
eation was often aided by the cystoscopic placement of fi-
ducial markers (used in 64 % of patients). At first, titanium
clips were used [33], which were replaced by lipiodol in
2006 [34]. At the introduction of intensity-modulated
radiotherapy (IMRT), the pelvic lymph nodes, prostate,
rectum, small bowel cavity and femoral heads were also de-
lineated on the planning CT scan. Three different planning
techniques have been used between 2003 and 2013, which
are described below. Table 1 lists the number of patients
treated with each radiotherapy planning technique. Table 2
provides an overview of the used techniques.
Before 2009, a conformal four-field box was used for
the elective field, and the concomitant boost was deliv-
ered using 2–4 conformal beams. The cranial limit of
the elective field was the L5-S1 interspace and the cau-
dal limit was 5 mm caudal of the symphysis. Lateral
margins were 10 mm beyond the maximal width of the
bony pelvis, whereas the anteroposterior margins on the
lateral fields were 15 mm beyond the bladder. The plan-
ning target volume (PTV) for the tumor, i.e. PTVboost,
was obtained by expanding the GTV with a 15–20 mm
margin in case no fiducial markers were present, as op-
posed to 10 mm in case of markers. When markers were
not present, an adaptive margin strategy for PTVboost was
used, for which the GTV was redelineated on daily repeat
CT scans acquired during the first week [17]. A summa-
tion of all GTV delineations was then expanded with
10 mm to create a second PTVboost, which was used from
the second week onwards. Weekly offline position verifi-
cation was performed using electronic portal images,
which was replaced by cone beam CT (CBCT) in 2007.
From 2009 onwards, patients were treated with an
IMRT technique. For this, a PTVelective was created by
expanding the combined bladder, prostate and lymph
node delineations with 15 mm in cranial and anterior di-
rections, and 8 mm in all other directions. PTVboost was
created as described before. Before October 2011, pa-
tients were treated with two separate IMRT-plans with 5
or 7 beams, for both the PTVelective and the concomitant
PTVboost [15]. After October 2011, the boost dose was
delivered simultaneously integrated with the elective
dose. Standard planning objectives were used to obtain a
target coverage of 95 % of the prescribed dose to 99 % of
the PTV, while keeping dose to the organs at risk as low
as possible. The introduction of IMRT was accompanied
by the introduction of daily image-guidance using CBCT
scans.




aAccording to UICC (TNM) classification
bPatients with positive lymph nodes were not referred for radical radiotherapy.
However, patients with one clinically dubious but not pathologically proven
local node were included
Table 2 Treatment planning and delivery methods
Elective Boosta
Dose Target organs PTV Doseb Delivery
3D-conformal 40 Gy Bladder, prostate, and pelvic lymph nodesc Box technique, based on
anatomical landmarks
55–60 Gy Concomitant
IMRT 40 Gy Bladder, prostate, and pelvic lymph nodesc Cranially and anteriorly: 15 mm. 55–60 Gy Concomitant
Other directions: 8 mm 55–60 Gy Simultaneously integratedd
VMAT 40 Gy Bladder, and pelvic lymph nodesc Cranially and anteriorly: 13 mm. 55–60 Gy Simultaneously integrated
Other directions: 7 mm
aIn case fiducial markers were present, a uniform boost margin of 10 mm was used. Otherwise, an adaptive margin strategy was employed
bA dose of 60 Gy was standard after 2006. 55 Gy was chosen only when a dose of 60 Gy would result in a too high small bowel dose
cLymph nodes were excluded from the elective field in case of comorbidities that required a target volume reduction
dSimultaneous integration of the boost plan with the elective plan was implemented after October 2011
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In 2012, rotational delivery of IMRT, i.e. volumetric
modulated arc therapy (VMAT), was implemented at
our department. Margins to create PTVelective were re-
duced to 13 mm cranially and anteriorly, and 7 mm in
all other directions, and the prostate was removed from
the elective target volume for tumors not located in the
bladder neck or prostatic urethra. The previously de-
scribed adaptive margin strategy was used for PTVboost
in case no markers were present, otherwise a uniform
margin of 9 mm was used. A daily simultaneously inte-
grated dose of 0.75–1 Gy was delivered to PTVboost.
Dual arc VMAT plans were created, and the same plan-
ning objectives were used as for IMRT.
Follow-up
All patients that started treatment were included in the
analysis of overall survival. Six patients who did not
complete treatment were excluded from locoregional
control analysis. Patients were seen by their radiation
oncologist every week during the treatment course,
1 month after treatment, every 3 months thereafter for
the first year, every 6 months thereafter up to 3 years,
and once yearly up to 5 years. A cystoscopy was per-
formed at 2 months after treatment and thereafter every
6 months. In case of locoregional symptoms or when
endoscopically a non-complete response was observed,
an additional cystoscopy or CT scan was performed.
Complete response was defined as endoscopically no
signs of vital tumor, whereas a partial response was de-
fined as a tumor mass reduction > 50 %. All invasive and
non-invasive recurrences in the bladder were scored as
local progression. Urinary and intestinal toxicity were
scored according to the Common Terminology Criteria
for Adverse Events (CTCAE) version 4.0. Acute toxicity
was scored as the maximum toxicity during treatment
or the first 3 months thereafter, whereas late toxicity was
the maximum toxicity occurring after 3 months. Bladder
capacity was estimated by the patient, both before treat-
ment and during follow-up. To this end, patients were
asked to measure their maximum voiding volume at
home, by voiding in a urinal or cup with volumetric in-
dications. In addition, patients were asked during follow-
up if their voiding capacity was improved or worsened
compared to the initial capacity before treatment.
Statistical analysis
All time intervals were calculated from the start of
radiotherapy treatment. Locoregional control was de-
fined as no histological proven nodal or bladder recur-
rence, whereas distant control was defined as no
evidence of distant metastasis. Bladder-intact survival
was defined as the survival without a muscle-invasive re-
currence (either no recurrence or a successfully treated
superficial recurrence) and without a salvage cystectomy.
The Kaplan-Meier method was used to estimate survival.
Possible predictors for survival and locoregional re-
currence were examined in univariate cox proportional
hazard regression analyses. Hazard ratios (HR) were calcu-
lated, with associated 95 % confidence intervals (CI) and
p-values. For predictors with continuous values both a lin-
ear and non-linear (i.e. cubic spline) association with the
specific outcome were tested. The toxicity scores were
dichotomized into grade ≥ 1, grade ≥ 2 and grade ≥ 3.
Possible predictors for toxicity were analyzed using logistic
regression in case of predictors with continuous values, or
the χ2 test for dichotomous predictors. The difference in
pre- and posttreatment functional bladder capacity was
tested using a paired t-test. A p-value < 0.05 was consid-
ered statistically significant, and statistical analysis was
performed using R (version 3.1.0, The R Foundation for
Statistical Computing, Vienna, Austria).
Results
The median time of follow up was 23.7 months. First re-
sponse measurements (n = 106) showed a complete re-
sponse in 92 patients (87 %), and a partial response in
11 patients (10 %). One patient had stable disease, and 2
patients showed progression. Out of all 118 patients, 20
patients (17 %) developed a recurrence in the bladder
during follow-up, of which 3 patients had a nodal recur-
rence. Four patients (3 %) developed a nodal recurrence
without bladder recurrence, and 27 patients (23 %) de-
veloped a distal recurrence. Of the local recurring pa-
tients, 9 patients (45 %) experienced both a locoregional
and distal recurrence. Six bladder recurrences were
superficial and were treated with TUR-B and mitomycin
C installations, whereas in the remaining 14 patients,
local recurrences were muscle-invasive.
The overall survival after 3 years was 44 % (95 % CI
36–55 %; Fig. 1). 37 patients died with bladder carcin-
oma, whereas 24 patients died from intercurrent disease.
Two patients died from treatment complications.
Bladder-intact survival after 3 years was 84 % (95 % CI
75–92 %). The 3-year locoregional and distant control
rates were 73 % (95 % CI 64–84 %; Fig. 2) and 74 %
(95 % CI 65–84 %), respectively.
On univariate analysis, a significant difference in overall
survival or locoregional disease recurrence was not found
for patients treated with either 3D-conformal radiotherapy
or IMRT/VMAT. The only significant predictors for sur-
vival were age and not completing treatment (Tables 3
and 4). For locoregional disease recurrence, only the pres-
ence of hydronephrosis was a statistically significant pre-
dictive factor (Table 3). Locoregional control after 3 years
was similar for patients receiving either 55 or 60 Gy, with
72 and 74 %, respectively (p = 0.55). The prognostic value
for none of the predictors improved by assuming a non-
linear relationship.
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Acute intestinal and urinary toxicity was scored in 72
patients. Of these, 19 % experienced grade 2 or higher
intestinal toxicity, compared to 26 % for urinary toxicity
(see Fig. 3a). Late toxicity was scored in 100 patients.
Late intestinal and urinary toxicity grade ≥ 2 was seen in
5 and 14 % of these patients, respectively (see Fig. 3b).
Grade 3 intestinal toxicity was seen in 1 patient, and
grade 4 in 2 patients. In 1 patient, grade 4 urinary tox-
icity was observed.
Univariate analysis revealed that the use of IMRT, com-
bined with daily image-guidance, reduced late intestinal
toxicity from 20 % for the conformal box technique, to
5 % for the intensity-modulated techniques (p = 0.05). In
addition, the introduction of IMRT also influenced acute
urinary toxicity (grade ≥ 3 toxicity reduced from 22 to 2 %,
p = 0.02). Acute urinary toxicity was furthermore influenced
by the use of fiducial markers, with a reduction in grade ≥ 2
toxicity from 53 % without markers, to 17 % with markers
(p < 0.01). Logistic regression revealed a relationship be-
tween tumor size and acute intestinal and urinary toxicity,
with tumor sizes of 2, 4, and 6 cm corresponding to risks of
grade ≥ 1 acute intestinal toxicity of 45, 79, and 94 %, re-
spectively (p < 0.01), and risks of grade ≥ 3 urinary toxicity
of 1, 4 and 18 %, respectively (p = 0.04). Other characteris-
tics were not predictive for either late intestinal or urinary
toxicity (see Additional file 1: Table S1-S3).
Of the 96 patients for which information about blad-
der function is available, 92 % reported a stable or im-
proved bladder function. Functional bladder capacity
increased significantly, from a median of 200 ml before,
to 250 ml after treatment (p = 0.004).
Discussion
In the present study, we found a 3-year overall survival
of 44 % for patients treated with TUR-B and radiother-
apy with a focal simultaneous boost for bladder cancer,
with a 3-year locoregional control of 73 %. Of the pa-
tients that were still alive after 3 years, 83 % had an in-
tact bladder. We found acute urinary and intestinal
toxicity rates grade ≥ 2 of 26 and 19 %, respectively,
whereas late urinary and intestinal toxicity grade ≥ 2 was
14 % and 5 %, respectively. Toxicity rates were lower for
patients treated with IMRT or fiducial markers around
the tumor.
Our results are similar compared to a multicenter
phase III trial by James et al., in which 360 patients were
randomly assigned to undergo radiotherapy either with
or without synchronous chemotherapy [6]. When com-
paring the radiotherapy-only results from their study
with the current study, similar 3-year overall survival
rates were found (Fig. 1) [6]. However, the results from
chemoradiation as reported by James et al. compare fa-
vorably to our results, with a 3-year overall survival for
chemoradiation of 57 %, compared to 44 % for the
present study (Fig. 1). Our low survival rate probably re-
flects the selection of elderly or medically frail patients,
who are likely to have a shorter survival independent of
their bladder cancer or treatment. The 3-year locoregio-
nal control of 73 % found in the current study, compares
favorably with other studies reporting on patients treated
with radiotherapy only, which present rates of 53–64 %
[22, 25, 27, 28]. The exclusion of patients that did not
complete radiotherapy, and patients with multifocal tu-
mors, will partly account for this effect. The higher ac-
curacy of dose delivery, by means of fiducial markers
and position verification with daily CBCT, may also con-
tribute to the high locoregional control rate. Locoregio-
nal control was not influenced significantly by the tumor



















Fig. 1 Overall survival (95 % confidence intervals depicted in grey
dashed lines)





















Fig. 2 Locoregional control (95 % confidence intervals depicted in
grey dashed lines)
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Table 3 Prognostic value for overall survival and locoregional recurrence of patient and tumor characteristics
Prognostic factors Overall survival Locoregional recurrence
n HR 95 % CI p n HR 95 % CI p
Age 118 1.0 (1.0;1.1) 0.02 112 1.0 (0.95;1.0) 0.89
Tumor size 117 1.0 (0.90;1.2) 0.62 111 1.0 (0.76;1.3) 0.99
Residual mass after resectiona
Yes 57 52
Possibly 27 0.81 (0.45;1.5) 0.49 27 0.83 (0.29;2.4) 0.73
No 16 0.47 (0.20;1.1) 0.09 15 0.80 (0.22;2.9) 0.73
Tumor location
Not mobile part 27 25
Mobile part 91 1.05 (0.61;1.8) 0.85 87 0.85 (0.34;2.1) 0.73
Clinical lymph node involvement
No 109 103
Yes 9 0.52 (0.19;1.4) 0.20 9 1.5 (0.44;5.0) 0.53
Hydronephrosis
No 97 92
Yes 21 1.29 (0.73;2.3) 0.38 20 2.9 (1.2;6.8) 0.01
Tumor stage
T2-T3 108 103
T4 10 1.05 (0.45;2.4) 0.91 9 0.52 (0.07;3.8) 0.23
NB. Due to exclusion of patients receiving less than their prescribed dose for the analysis on local recurrence, total amount of patients in this analysis is 112,
which is different from the analysis on overall survival. In addition, residual mass after resection and tumor size were not known for all patients
aAs assessed on the CT scan made for planning purposes
Table 4 Prognostic value for overall survival and locoregional recurrence of treatment characteristics
Prognostic factors Overall survival Locoregional recurrence
n HR 95 % CI p n HR 95 % CI p
Received radiotherapy dose
55 Gy 57 57
60 Gy 55 0.70 (0.44;1.1) 0.15 55 0.81 (0.36;1.8) 0.61
< prescribed dose 6 5.3 (2.1;13.0) <0.001
Radiotherapy technique
3D-conformal 67 63
IMRT/VMAT 51 1.05 (0.66;1.7) 0.83 49 0.97 (0.43;2.2) 0.95
Treated with image-guidance
No 42 40
Yes 76 1.43 (0.88;2.3) 0.15 72 1.0 (0.45;2.4) 0.93
Elective lymph node irradiation
No 24 23
Yes 94 0.60 (0.36;1.0) 0.06 89 1.1 (0.37;3.1) 0.90
Use of fiducial markers
No 43 40
Yes 75 0.93 (0.59;1.46) 0.75 72 0.83 (0.37;1.9) 0.66
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dose (55 versus 60 Gy), but tumor dose also did not in-
fluence toxicity. In the absence of concurrent chemo-
therapy, a tumor dose of 60 Gy is therefore still
advocated, except when small bowel dose constraints are
exceeded, in which case a dose of 55 Gy can be applied.
Other studies report late urinary and intestinal toxicity
rates grade ≥ 2 of 10–17 %, and 7–10 % [22, 27–29], re-
spectively. This is comparable to our results, with rates
of 14 and 5 %, respectively. Since the risk of global blad-
der injury increases for doses over 50 Gy [35], the vol-
ume receiving the boost dose of 55 Gy should be as
small as possible. This is reflected in our finding that the
use of fiducial markers resulted in lower rates of acute
urinary toxicity; when markers were used, the margins
around the tumor were smaller, and a smaller volume of
the non-involved bladder received 55 Gy. In addition,
studies based on high-dose whole bladder irradiation as
opposed to a tumor boost, report higher rates of late
urinary toxicity grade ≥ 1: rates of 36–62 % have been re-
ported, compared to 27 % we found [22, 28]. Regarding
IMRT, we found a trend towards lower rates of grade ≥ 2
acute intestinal toxicity compared to a box technique
(decrease from 33 % to 12 %, p = 0.06), which confirms
the results of Søndergaard et al. [26]. This finding is in
line with the lower bowel dose resulting from both the
more conformal treatment technique, as well as the use
of smaller margins [15, 16, 36]. The overall rates of tox-
icity in the present series were lower than the series by
Søndergaard et al. which could be explained by a lower
dose to the bladder and lymph nodes (40 versus 48–
60 Gy). Since the volume of bowel receiving at least
45 Gy is most predictive for intestinal toxicity [26, 37], a
dose prescription ≥ 40 Gy is expected to result in more
intestinal toxicity.
The significant reduction found in both acute urin-
ary and intestinal toxicity can be attributed to the
introduction of fiducial markers, IMRT and daily
image-guidance. Further increasing treatment accuracy,
with the inherent reduction in margin size, could there-
fore further decrease toxicity. Adaptive strategies are vital
in increasing treatment accuracy, since the interfractional
movement of the bladder is a very large source of uncer-
tainty. It has been shown that with an adaptive strategy,
the dose to the bowel can be reduced while maintaining
or improving target coverage [20, 21]. Further studies re-
garding outcome will determine whether this also results
in a lower toxicity and a possibly higher local control.
Limitations of the present study are the retrospective
nature of the data, and patient inclusion from a single
institute. Our sample size was large compared to similar
studies [22, 23, 25, 28], but was still relatively small con-
cerning the univariate analyses on predictors for sur-
vival, recurrence and toxicity. For instance for survival,
we only found age as predictor, whereas previously also
tumor grade, tumor stage, performance status, complete
resection and lymphatic invasion have been reported as
predictors [10, 12, 29, 38]. In agreement with previous
studies, we found hydronephrosis as a significant pre-
dictor for locoregional recurrence [9, 22, 28, 39]. It is
possible that certain variables will prove to be predictors
for several outcomes when a larger patient group is ana-
lyzed. Another limitation was the incomplete toxicity
data, but this occurred randomly due to differences be-
tween physicians in the scoring of toxicity. A final limi-
tation is the fact that patients treated with IMRT and
VMAT were grouped together for univariate analyses.
The PTV volume for VMAT is smaller since the intro-
duction of VMAT coincided with the decision to exclude
the prostate from the target volume, as well as a minor
margin reduction, and this could have influenced the re-
sults. However, due to the small number of patients
treated with VMAT, and the relatively small expected
improvement in dose distribution [16], the effect on the
analysis is assumed to be negligible.





































Fig. 3 Acute and late toxicity. a Acute toxicity. b Late toxicity. Light bars represent urinary toxicity, dark bars represent intestinal toxicity
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Conclusion
We found a 3-year overall survival of 44 % for patients
treated with TUR-B and curative radiotherapy for blad-
der cancer. Three-year locoregional control was 73 %,
with low rates of acute and late urinary and intestinal
toxicity. Toxicity rates were reduced when using IMRT
and fiducial markers. Radical radiotherapy using a focal
simultaneous boost is therefore a feasible and effective
treatment option for elderly or unfit patients with
muscle-invasive bladder carcinoma, with a high change
of preservation of bladder function.
Additional file
Additional file 1: Table S1. Prognostic factors for toxicity grade ≥ 1.
Table S2. Prognostic factors for toxicity grade ≥ 2. Table S3. Prognostic
factors for toxicity grade ≥ 3. (PDF 251 kb)
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